Completed PHASE3 INTERVENTIONAL 6-arm NCT00830960

A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome

A Comparison of Platelet Inhibition Following Prasugrel or Clopidogrel Administration in Asian Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention

Sponsor: Daiichi Sankyo Co., Ltd.

Conditions Acute Coronary Syndrome

Interventions Clopidogrel Prasugrel

Updated 7 times since 2017 Last updated: Sep 22, 2011 Started: Feb 28, 2009 Primary completion: Jun 30, 2010 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00830960, this PHASE3 trial focuses on Acute Coronary Syndrome and remains completed. Sponsored by Daiichi Sankyo Co., Ltd., it has been updated 7 times since 2009, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daiichi Sankyo Co., Ltd.
Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bangkok, Thailand , Beijing, China , Chiang Mai, Thailand , Daegu, South Korea , Guangzhou, China , Hangzhou, China , Kwangju, South Korea , Nanjing, China , Seongnam-si, South Korea , Seoul, South Korea and 8 more locations